This evidence reveals a criticism of the screening methodology to be resolved promptly; indeed, the coexistence of homozygous SMN1 defect and RPP30 polymorphism would lead to total absence of amplification plot for both targets, making identification of a true positive SMA infant difficult. Here, RPP30 is linked to proximal spinal muscular atrophy.